Assessing High-Dose Versus Standard-Dose Influenza Vaccine Protection Against Severe Disease Outcomes - European Medical Journal

This site is intended for healthcare professionals

Assessing High-Dose Versus Standard-Dose Influenza Vaccine Protection Against Severe Disease Outcomes

Download PDF

The study and publication of this infographic were funded by Sanofi.


This infographic summarizes findings from FLUNITY-HD, the largest ever individually randomized influenza vaccine effectiveness trial. Conducted across nearly half a million older adults, the study provides valuable real-world insights into the protection offered by high-dose versus standard-dose influenza vaccines.

Explore

  • How the innovative, pragmatic design of FLUNITY-HD reflects real-world clinical practice
  • The scope and methodological rigor behind its nearly 466,000-participant dataset
  • Key findings on high-dose influenza vaccine performance across severe outcomes, including hospitalizations
  • The consistency and generalizability of results across multiple flu seasons and regions

View the infographic above to explore the data in detail.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.